The Latest Breaking News from BofA

The last time the Fed cut rates against rising inflation was right before the Great Financial Crisis. BofA warns of the 'Ghosts of 2007'

Conditions are like they were in 2007, or in the late 1990s, depending on how you look at the Fed raising rates during rising inflation, and the top 50 stocks dominating.

Fortune · Aug 19, 2025

Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage

Carlsmed Inc. (NASDAQ:CARL), an AI-powered innovator in spine surgery, is poised for significant growth following key advancements and strong analyst projections.

Benzinga · Aug 18, 2025

GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?

GoodRx stock soars after announcing GLP-1 partnership with Novo Nordisk. A Bank of America analyst recommends selling GDRX shares into the strength before they crash again.

Barchart · Aug 18, 2025

Bank of America sees stagflation, not recession—and no rate cut this year. It’s because of 2 specific Trump policies

It all comes down to the labor market, immigration, and tariffs. What is really going on in terms of how many workers are available?

Fortune · Aug 8, 2025

As Super Micro Computer Stock Absolutely Plunges, Should You Buy the SMCI Dip?

Super Micro stock tanks on disappointing Q4 earnings and weaker-than-expected guidance. Here’s why SMCI shares aren’t worth buying on the post-earnings decline.

Barchart · Aug 6, 2025

Here’s what the doomsayers are getting wrong about the job market, according to a Wall Street veteran

“This implies that the weak gains in payrolls in recent months might have something to do with the supply of labor.”

Fortune · Aug 4, 2025

Ford's Q2 Shines, But Analysts Warn Of Recall Hangover And Cost Pressures

Ford Motor Company (NYSE:F) shares are trading higher on Thursday after the automaker posted second-quarter results that exceeded Wall Street expectations on Wednesday, driven by solid vehicle volumes and favorable pricing trends.

Benzinga · Jul 31, 2025

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck Co. Inc. (NYSE:MRK) is the latest to face these challenges, as its recent earnings report reveals a mixed bag of successes and setbacks.

Benzinga · Jul 30, 2025

‘Not just a cyclical recovery, but a boom.’ BofA says a ‘key tail risk’ is that the Trump economy will actually start to take off

“Today a confluence of factors argue that the key tail risk that may not be priced in is not just a cyclical recovery, but a boom,” BofA Research analysts write.

Fortune · Jul 28, 2025

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Benzinga · Jul 23, 2025